Zentalis Pharmaceuticals, Inc.

How big is Zentalis Pharmaceuticals, Inc.?

As of Jun 18, Zentalis Pharmaceuticals, Inc. has a market capitalization of 107.93 million, with net sales of 26.86 million and a net profit of -224.19 million over the last four quarters.

Market Cap: As of Jun 18, Zentalis Pharmaceuticals, Inc. has a market capitalization of 107.93 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Zentalis Pharmaceuticals reported net sales of 26.86 million and a net profit of -224.19 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 337.19 million and total assets of 430.34 million.

What does Zentalis Pharmaceuticals, Inc. do?

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for cancer. It has a market cap of approximately $107.93 million and reported a net profit loss of $48 million as of March 2025.

Overview: <BR>Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -48 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 107.93 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.13 <BR>Return on Equity: -71.60% <BR>Price to Book: 0.37 <BR><BR>Contact Details: <BR>Address: 530 Seventh Avenue, Suite 2201, Suite 2201 NEW YORK NY : 10018 <BR>Tel: ['1 212 4333791', '1 64 782931'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.zentalis.com/

Should I buy, sell or hold Zentalis Pharmaceuticals, Inc.?

Who are in the management team of Zentalis Pharmaceuticals, Inc.?

As of March 2022, Zentalis Pharmaceuticals, Inc.'s management team includes Dr. Anthony Sun as Executive Chairman, President, and CEO, along with Directors Mr. Cam Gallagher and Independent Directors Dr. Kimberly Blackwell, Mr. David Johnson, and Mr. Karan Takhar.

As of March 2022, the management team of Zentalis Pharmaceuticals, Inc. includes Dr. Anthony Sun, who serves as the Executive Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Mr. Cam Gallagher as a Director, and Dr. Kimberly Blackwell, Mr. David Johnson, and Mr. Karan Takhar as Independent Directors.

Is Zentalis Pharmaceuticals, Inc. overvalued or undervalued?

As of May 7, 2024, Zentalis Pharmaceuticals is considered risky and overvalued due to significant losses and poor performance metrics, with a year-to-date return of -50.83%, compared to the S&P 500's 12.22%.

As of 7 May 2024, Zentalis Pharmaceuticals, Inc. has moved from a grade of does not qualify to risky, indicating increased concerns regarding its valuation. The company appears to be overvalued, especially given its significant losses and poor performance metrics. Key ratios include a Price to Book Value of 0.37, an EV to EBIT of 1.12, and an EV to EBITDA of 1.13, which suggest that the company's valuation does not align well with its financial performance.<BR><BR>In comparison to peers, Zentalis Pharmaceuticals has a valuation of -0.7834, while Prothena Corp. Plc has a valuation of -1.6907, indicating that Zentalis is relatively better positioned but still in a risky category. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -50.83% compared to the index's 12.22%, reinforcing the notion that it is overvalued in its current state.

Is Zentalis Pharmaceuticals, Inc. technically bullish or bearish?

As of September 8, 2025, Zentalis Pharmaceuticals, Inc. shows a mildly bearish trend with mixed technical indicators, underperforming the S&P 500 significantly year-to-date and over the past year.

As of 8 September 2025, the technical trend for Zentalis Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD is mildly bullish, but the daily moving averages indicate a bearish stance. The Bollinger Bands show a mixed signal with weekly mildly bullish and monthly bearish readings. The KST is bullish on a weekly basis, while the Dow Theory is mildly bearish. The OBV is also mildly bearish on the weekly timeframe. <BR><BR>Zentalis has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -50.83% versus the S&P 500's 12.22%, and a one-year return of -64.18% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish.